Novel Chirality-Converted Peptide Fights Bacterial Infection and Restores Gut Health

Polymicrobial infections, particularly those involving Vibrio species, pose significant threats to both aquaculture and human health, often leading to severe gastrointestinal diseases and high mortality rates. Current antibiotic treatments can disrupt the delicate balance of the gut microbiota, leading to dysbiosis and potential long-term health issues. This study addresses the urgent need for novel antimicrobial strategies that effectively combat bacterial pathogens while simultaneously preserving or restoring gut microbial equilibrium.

The study found that VibrioGuard-12 significantly reduced bacterial load and improved survival rates in infected zebrafish. The 1.0 mg/kg dose of VibrioGuard-12 resulted in a remarkable 85% survival rate, compared to only 20% in the untreated control group (p<0.001). Bacterial counts in the gut and liver were reduced by >3.5-fold in peptide-treated groups compared to controls. The most impactful finding was that VibrioGuard-12 not only cleared the infection but also preserved gut microbiota diversity, with the Shannon index showing a 1.8-fold increase compared to the antibiotic-treated group (p<0.01), which exhibited significant dysbiosis. Furthermore, inflammatory markers like IL-6 were reduced by 65% in the VibrioGuard-12 group, indicating a strong anti-inflammatory effect.